Back to top

Image: Bigstock

Top Ranked Growth Stocks to Buy for June 7th

Read MoreHide Full Article

Here are four stocks with Zacks Rank #1 (Strong Buy) and strong growth characteristics for investors to consider today, June 7th:

The Chemours Company (CC - Free Report) : This chemical company has witnessed the Zacks Consensus Estimate for its current year earnings rising 19.3% over the last 60 days.

Chemours has a PEG ratio 0.8, compared with 1.54 for the industry. The company possesses a Growth Score of A.

Boise Cascade Co (BCC - Free Report) : This integrated wood products manufacturer and building materials distributor has witnessed the Zacks Consensus Estimate for its current year earnings rising 4.2% over the last 60 days.

Boise Cascade, L.L.C. Price and Consensus

 

Boise Cascade, L.L.C. Price and Consensus | Boise Cascade, L.L.C. Quote

Boise Cascade has a PEG ratio of 0.97, compared with 2.49 for the industry.  The company possesses a Growth Score of B.

Mercadolibre, Inc. (MELI - Free Report) : This major online trading platform in Latin America has witnessed the Zacks Consensus Estimate for its current year earnings rising 4.2% over the last 60 days.

MercadoLibre, Inc. Price and Consensus

 

MercadoLibre, Inc. Price and Consensus | MercadoLibre, Inc. Quote

Mercadolibre has a low PEG ratio of 2.05. The company possesses a Growth Score of B.

Big 5 Sporting Goods Corp.  (BGFV - Free Report) : This sporting goods retailer has witnessed the Zacks Consensus Estimate for its current year earnings rising 16.8% over the last 60 days.

Big 5 Sporting Goods has a PEG ratio of 0.95, compared with 1.26 for the industry. The company possesses a Growth Score of A.

See the full list of top ranked stocks here

Learn more about the Growth score and how it is calculated here

 5 Trades Could Profit ""Big-League"" from Trump Policies  

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>